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Fall in C-Peptide During First 2 Years From Diagnosis
Evidence of at Least Two Distinct Phases From Composite
Type 1 Diabetes TrialNet Data
Carla J. Greenbaum,1 Craig A. Beam,2 David Boulware,2 Stephen E. Gitelman,3
Peter A. Gottlieb,4 Kevan C. Herold,5 John M. Lachin,6 Paula McGee,6 Jerry P. Palmer,7
Mark D. Pescovitz,8† Heidi Krause-Steinrauf,6 Jay S. Skyler,9 Jay M. Sosenko,9
on behalf of the Type 1 Diabetes TrialNet Study Group*
Interpretation of clinical trials to alter the decline in b-cell function
after diagnosis of type 1 diabetes depends on a robust understanding
of the natural history of disease. Combining data from the Type 1
Diabetes TrialNet studies, we describe the natural history of b-cell
function from shortly after diagnosis through 2 years post study
randomization, assess the degree of variability between patients,
and investigate factors that may be related to C-peptide preservation
or loss. We found that 93% of individuals have detectable C-peptide 2
years from diagnosis. In 11% of subjects, there was no significant fall
from baseline by 2 years. There was a biphasic decline in C-peptide;
the C-peptide slope was 20.0245 pmol/mL/month (95% CI 20.0271
to 20.0215) through the first 12 months and 20.0079 (20.0113
to 20.0050) from 12 to 24 months (P , 0.001). This pattern of fall
in C-peptide over time has implications for understanding trial
results in which effects of therapy are most pronounced early and
raises the possibility that there are time-dependent differences in
pathophysiology. The robust data on the C-peptide obtained un-
der clinical trial conditions should be used in planning and in-
terpretation of clinical trials. Diabetes 61:2066–2073, 2012
The natural history of type 1 diabetes (T1D) isarguably better understood than that of manyother autoimmune diseases, with decades ofstudies describing the disease course before and
after diagnosis. In addition to providing the backdrop for
studies to understand the etiopathology of T1D, such in-
formation is critical for the design and interpretation of
clinical trials to alter the progression of the disease.
The generally understood picture postdiagnosis is of an
inevitable fall in b-cell function within a few years after
diagnosis, and many studies point to variables that affect
the rate of fall, such as glycemic control, HLA type, age at di-
agnosis, and BMI.
There are several reasons to reexamine the natural
history of b-cell function. In recent years, changes in di-
abetes management and consequent improvement of gly-
cemic control have occurred. In addition, several studies
point to a changing HLA distribution in patients with di-
abetes (1,2), and the overall population generally has had
an increase in BMI (3,4). More provocative, there are in-
creasing reports of persistence of C-peptide in individuals
long after diagnosis (5) and emerging information from
autopsy studies (6) that suggest that the current paradigm
should be reconsidered. Furthermore, careful scrutiny of
placebo groups from published clinical trials demonstrates
major inconsistencies in changes in C-peptide over time
between studies, which may be attributable to character-
istics of the study populations, procedures used to assess
b-cell function, and/or analytic methods used for re-
porting data.
Type 1 Diabetes TrialNet is an international, multicenter
clinical trial network designed to alter the course of T1D,
either before diagnosis (prevention) or after clinical di-
agnosis, with the aim of prolonging b-cell functional sur-
vival. As of 2011, TrialNet had acquired data up to 24
months from diagnosis from three clinical trials in individ-
uals with recently diagnosed T1D (7–9). These studies all
had similar entry criteria, standardized approaches to di-
abetes management, and defined protocols for assessment
of b-cell function that are highly reproducible (10). In this
analysis, we take advantage of this robust dataset to de-
scribe the natural history of b-cell function in individuals
through 2 years postrandomization, assess the degree of
variability between patients, and investigate factors that
may be related to C-peptide at and postdiagnosis.
RESEARCH DESIGN AND METHODS
Data from 191 subjects were included in this analysis, including all subjects from
one study in which the intervention had no effect on b-cell function (7) and the
placebo-treated subjects from two other studies (8,9). Inclusion of the actively
treated subjects from the negative study had no appreciable impact on the
results (see below). All subjects or their parents gave written informed consent
and assent as appropriate prior to participation in these studies. Pertinent study
entry criteria for randomization include peak C-peptide during mixed-meal
tolerance test (MMTT) $0.2 pmol/mL, positive for at least one diabetes auto-
antibody, diagnosis of T1D within the previous 100 days, and age 7–45 years. To
ensure metabolic stability, no MMTTs were performed before 21 days after
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diagnosis. The mean (median) time from diagnosis to MMTT was 79 (55) days.
The study protocol called for subjects to be contacted by the study team every 2
weeks to evaluate and make recommendations to ensure tight glycemic control.
The mean HbA1c at 1 and 2 years was 7.3 (61.5) and 7.6% (61.5), respectively.
MMTT. As previously described (10), subjects underwent a 2- or 4-h MMTT
under the following circumstances: tests were started before 10 A.M., fasting
glucose was required to be 70–200 mg/dL, and long-acting insulin was permitted
but no short acting insulin (including no pump bolus) was allowed within 2 h
before start of test. A standard preparation of fat, carbohydrate, and protein
(Boost-HP; Nestle Health Care Nutrition, Inc.) was used at a dose of 6 mg/kg to
a maximum of 360 mL.
Analysis. Full details of analyses are presented in the Supplementary Material.
Key points are summarized here.
C-peptide values recorded as below “lower limit of detection” (LLD) were
assigned the value of one-half the LLD. C-peptide area under the curve (AUC)
was calculated using the trapezoidal method. Areas were then divided by the
time period of the test, 120 or 240 min as indicated. Undetectable C-peptide on
MMTT was defined as all timed values on the MMTT below the LLD.
Maintenance of C-peptide. Subjects were classified as having maintained
C-peptide over time if there was no change from baseline to each of the time
points after baseline. To account for statistical variation in C-peptide mea-
surements, we used three definitions of maintained C-peptide that are suggested
by two published studies. All three definitions are similar in that they each
consider no change or an increase from baseline to represent a positive re-
sponse. They differ in the amount of decrease they allow for a subject to still be
classified as having maintained C-peptide:
1) “Percentage Change” definition of maintenance of C-peptide: Subject
whose follow-up C-peptide value is no more than 7.5% below baseline.
This was defined as “responder” to therapy in work published by Herold
et al. (11).
2) “Inter-test Variability” definition of maintenance of C-peptide: The MMTT/
GST (glucagon stimulation test) (10) was a test-retest study comparing
C-peptide measurements between the MMTT and the GST. In the MMTT/GST
study, individuals underwent two MMTT within a 1-month period. We
used the MMTT data from that study to estimate inter-test variability of
C-peptide determined byMMTT. In the current analysis, someone whose change
from baseline was either nonnegative or if negative, was no more than 1
inter-test SD below baseline, was defined as having maintained C-peptide.
3) “CV” definition of maintenance of C-peptide: Using MMTT data from the
MMTT/GST study, the median coefficient of variation (CV) among the sub-
jects in that study was determined. In the current analysis, the CV for each
subject was computed between the baseline and each of the time points
(see Supplementary Material for details). A subject was then classified as
having maintained C-peptide whenever his or her change from baseline
was either nonnegative or if negative, represented a CV less than the me-
dian CV found in the MMTT/GST study.
We also evaluated the occurrence of an increase in C-peptide that is beyond
the amount expected from simple inter-test variability (i.e., an increase of at
least 1 inter-test SD from baseline).
Associations between C-peptide measures with baseline covariates were
assessed with Spearman correlation for continuous covariates and with
ANOVA for categorical covariates. The time course of the proportion of
subjects with detectable C-peptide values and the proportion of subjects with
peak C-peptide $0.2 pmol/mL were estimated with the Kaplan-Meier
method.
The relationship of C-peptide across time with baseline covariates was
evaluated with mixed linear models and, thus, slopes relating C-peptide and time
were estimated for each individual subject. Slopes of C-peptide versus time were
estimated for subgroups using themean slope of individuals in that group and the
estimates displayed in fan plots. The joint influence of baseline covariates on the
longitudinal change in C-peptide was assessed with multivariable models. Only
covariates that were found significant (P , 0.05) in univariable analysis were
included in the multivariable models. Piecewise linear regression was used to
test the data-driven hypothesis that the slope of C-peptide AUC was the same
before and after 1 year postbaseline (12). Slopes unadjusted for covariates were
compared between the three end points (fasting, peak, and AUC) using the
multivariate analysis described in the Supplementary Material.
Our study combined data from placebo- and active-treated subjects from the
negative Type 1 Diabetes TrialNet MMF/DZB study to increase the number of
observations. To evaluate whether inclusion of the actively treated MMF/DZB
subjects significantly altered our findings, we replicated the multivariate
analyses using a variable to indicate treatment in the MMF/DZB study. This
variable was never statistically significant at the P, 0.05 level. In addition, the
novel observation of a biphasic fall of C-peptide (described below) was
present with or without the actively treated subjects.
RESULTS
The demographic and baseline characteristics of the 191
subjects included in this analysis are shown in Table 1.
Correlations of baseline characteristics with the peak and
AUC C-peptide values from their baseline MMTT are also
noted in Table 1. Baseline variables that were significantly
associated with both peak and AUC C-peptide included age,
presence of another autoimmune disease, HbA1c, insulin
dose (units/kg/day), BMI and BMI z score, micro–insulin
autoantibody (mIAA) positivity, mIAA titer, and basophils.
At entry, all individuals were required to have a peak
C-peptide $0.2 pmol/mL. Over time, as shown in Fig. 1,
only 1% of individuals had undetectable C-peptide at 12
months after study entry and 7% had undetectable
C-peptide at 24 months. Post hoc analysis of Diabetes
Control and Complications Trial (DCCT) data has sug-
gested that individuals with a peak C-peptide on MMTT
$0.2 pmol/mL were less likely to have progression of
retinopathy and severe hypoglycemia than those with less
than that value (13). We therefore evaluated the time until
individuals reached this value. As shown in Fig. 1, 88% of
individuals continued to have peak C-peptide $0.2 pmol/mL
at 12 months of follow-up and 66% at 24 months.
We also evaluated changes of three end points from
the MMTT (fasting C-peptide, peak C-peptide, and AUC
C-peptide) during the 2 years of the study. Comparisons
between peak, AUC, and change from baseline using values
from the 4- and 2-h tests showed extremely high concor-
dance (Supplementary Table 1). Since, by protocol, there
were fewer 4-h tests performed, results from the 2-h MMTT
were used in subsequent analyses. The slope of the regres-
sion of each end point on time, measured in months from the
start of the study, was determined. Fasting C-peptide fell at a
rate of20.00766 0.0007, peak C-peptide at20.02226 0.0010,
and AUC C-peptide at 20.0172 6 0.0007 pmol/mL/month.
These slopes were each significantly different from each
other (P , 0.001), with fasting C-peptide having the
smallest change over time (Supplementary Table 2).
Examination of the plots of the mean AUC C-peptide over
time suggested a biphasic decline with differences in the
slope before and after 12 months (Fig. 2). This difference
was not explained by inclusion of individuals who lost
C-peptide during the study period because truncating either
those subjects or their data points below the LLD did not
affect this pattern. We further explored this data-driven
hypothesis using piecewise linear regression and found that
the decline after 12 months was significantly slower than
that seen during the first 12 months and that this was not
affected by age. The slope of the AUC C-peptide before 12
months was estimated to be 20.0245 pmol/mL/month (95%
CI20.0271 to20.0215) as compared with a slope of20.0079
(20.0113 to 20.0050) from 12 to 24 months (P , 0.001). In
a similar manner, the slope of the peak C-peptide before 12
months was 20.0318 (20.0357 to 20.0278) as compared
with a slope of 20.0089 (20.0136 to 20.0046) from 12 to
24 months (P , 0.001). The slope of fasting C-peptide
before 12 months was 20.03322 (20.03984 to 20.02659)
and after 12 months was 20.00867 (20.01626 to 20.00108)
(P , 0.001).
Inspection of each individual’s C-peptide data over time
shows the variability in slopes between individuals (Sup-
plementary Fig. 1). We then evaluated baseline factors that
may contribute to these differences in C-peptide slope
(Supplementary Table 3). Notable variables not found to
be associated with C-peptide over time included Tanner
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stage and class II HLA type categorized as DR3 or DR4 and
not DQB1*0602 or otherwise. Those variables found to be
significantly associated were then evaluated in a multivari-
able model. As shown in Table 2, only age and number of
basophils impacted C-peptide over time whether AUC,
peak, or fasting C-peptide was used. Additional baseline
variables significantly associated with stimulated measures
only (AUC and peak) were BMI z score and insulin dose.
We further explored the effect of age on C-peptide over
time by grouping individuals according to quartiles according
to age, taking the mean slope estimated by the multi-
variable model of AUC C-peptide. As shown in Fig. 3,
the youngest children (aged 7.7–12.3 years) started with
lower C-peptide values at their initial MMTT compared
with the other subjects. The three older quartiles (aged
12.4–46.1 years) were not different at their initial MMTT.
In contrast, the slopes of C-peptide over time showed
remarkable concordance in children among the three
youngest groups, distinct from that of subjects in the
oldest quartile.
TABLE 1
Demographic and baseline characteristics and correlations with peak and AUC C-peptide from baseline MMTT
n
Mean (SD) or
frequency (%)
Correlation with baseline
C-peptide: AUC (P value)a
Correlation with baseline
C-peptide: peak (P value)a
Age (years) 191 18.09 (8.84) 0.17 (0.02) 0.29 (,0.0001)
Age (categorical) (0.09) (0.03)
#12 36 18.85
12–17 86 45.03
$17 69 36.13
Race (0.24)b (0.07)b
Asian 4 2.09
Black/African American 2 1.05
White 178 93.19
More than one race 2 1.05
Other 5 2.62
Ethnicity (0.32) (0.71)
Hispanic or Latino 14 7.33
Not Hispanic or Latino 177 92.67
Sex (0.77) (0.75)
Male 119 62.30
Female 72 37.70
Duration of T1D to MMTT (days) 191 79.30 (18.62) 20.11 (0.14) 20.13 (0.07)
Other autoimmune disease (0.006) (0.004)
Yes 17 8.90
No 174 91.10
BMI 190 21.79 (0.34) 0.49 (,0.0001) 0.53 (,0.0001)
BMI z score 190 0.34 (1.00) 0.42 (,0.0001) 0.40 (,0.0001)
HLA (0.84) (0.63)
DR3 or DR4; not DQB1*0602 154 85.56
Not DR3 or DR4; or DQB1*0602 26 14.44
C-peptide (pmol/mL)
2-h AUC mean 180 0.71 (0.33) — 0.96 (,0.0001)
2-h AUC peak 190 0.93 (0.44) 0.96 (,0.0001) —
4-h AUC mean 176 0.71 (0.31) 0.96 (,0.0001) 0.96 (,0.0001)
4-h AUC peak 190 0.94 (0.44) 0.94 (,0.0001) 0.99 (,0.0001)
HbA1c 190 6.50 (1.07) 20.24 (0.001) 20.35 (,0.0001)
Insulin dose (units/kg) 185 0.37 (0.21) 20.34 (,0.0001) 20.33 (,0.0001)
mIAA (titer) 190 0.18 (0–5.68)c 20.23 (0.002) 20.28 (,0.0001)
mIAA (% positive) 88.42 (0.02) (0.003)
GAD65 (titer) 190 0.10 (20.02 to 1.22)c 0.008 (0.92) 0.08 (0.25)
GAD65 (% positive) 76.84 (0.66) (0.19)
ICA512 (titer) 190 0.51 (20.04 to 1.19)c 20.12 (0.13) 20.10 (0.19)
ICA512 (% positive) 72.11 (0.42) (0.20)
ICA (titer) 185 40.0 (0–20,480)c 20.03 (0.68) 20.02 (0.78)
ICA (% positive) 70.81 (0.11) (0.33)
Compete blood count
Hemoglobin 185 13.54 (1.15) 0.01 (0.93) 0.07 (0.35)
White blood cell 185 5.52 (1.68) 0.04 (0.66) 0.05 (0.50)
Polymorphonuclear leukocytes 184 51.98 (9.63) 0.19 (0.02) 0.18 (0.02)
Lymphocytes 184 35.87 (8.94) 20.16 (0.04) 20.18 (0.02)
Monocytes 184 7.63 (2.45) 20.06 (0.46) 20.04 (0.58)
Eosinophiles 183 3.45 (2.87) 0.04 (0.66) 0.10 (0.20)
Basophils 181 0.64 (0.54) 20.35 (,0.0001) 20.37 (,0.0001)
aFor numerical variables, Spearman correlation is reported. For categorical, ANOVA is used and only the P value is reported. bFor race, the
test is comparing white vs. nonwhite. cMedian (range); negative values set to missing in analysis.
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Additional exploratory analyses, such as considering
the C-peptide in relationship to the simultaneous glucose
value, neither improved the model nor changed the impact
of previously identified variables on the outcome measure.
We then evaluated time-related patterns of C-peptide
preservation, using the classification of subjects as having
maintained C-peptide or not, separately for each of the
three definitions introduced in RESEARCH DESIGN AND METHODS.
As shown in Table 3, large numbers of subjects could be
considered as having maintained C-peptide by any defini-
tion if all tests are taken into consideration. When limited to
comparing the baseline with the 1- or 2-year values alone, 33
(17%) and 21 (11%) maintained C-peptide as defined by the
CV definition, respectively, with similar values for the other
definitions as described in RESEARCH DESIGN AND METHODS.
Multivariable analysis found that age significantly increases,
and the presence of islet cell antigen (ICA)512 antibody
significantly decreases, the probability of having maintained
C-peptide by the CV definition at 2 years (odds ratio age
1.067 [95% CI 1.026–1.109]; ICA512 0.329 [0.162–0.667]).
In a similar way, we also investigated time-related pat-
terns of subjects who had strictly an increase in C-peptide
of at least 1 inter-test difference SD. There were 55 of 191
subjects who experienced at least one such increase during
the 2-year period. In a multivariable model, baseline pre-
dictors that enhanced the probability of this increase were
increased age, GAD65 antibody positivity, and Tanner stage.
Those that decreased the probability of an increase in
C-peptide were insulin dose and mIAA and ICA512 posi-
tivity and titers.
DISCUSSION
Loss of insulin secretion is the fundamental defect of T1D,
with natural history studies showing a decline before and
continuing after clinical diagnosis until a complete absence
of endogenous secretion occurs. This natural history serves
as the underlying rationale for studies to halt b-cell de-
struction. Slowing or stopping this loss of insulin secretion
prior to diagnosis would delay or prevent clinical onset of
FIG. 1. Percent of individuals with detectable C-peptide and C-peptide ‡0.2 pmol/mL over time.
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disease. Retention of endogenous insulin secretion after
diagnosis has been associated with clinical benefits as
shown by the DCCT, in which those with preserved
function obtained the benefit of intensive therapy (e.g.,
reduction of retinopathy) with less risk of severe hypo-
glycemia (14), and in islet transplant studies, in which
there is a reduction in hypoglycemia even when insulin
independence is not achieved (15).
Our data show that 93% of individuals who started with
C-peptide $0.2 pmol/mL have detectable C-peptide 2 years
from diagnosis, and ;66% are above the DCCT C-peptide
threshold associated with clinical benefit. Furthermore, in
contrast to both peak and AUC measures, there is limited
change in fasting C-peptide during 2 years from study en-
try, suggesting that use of nonstimulated C-peptide as an
outcome in clinical trials would make it a difficult end
point to demonstrate benefit of an intervention therapy.
Most important, our data indicate that the rate of fall is
not constant from study entry during the next 2 years. Our
data show a biphasic fall during this time; however, with
the limited number of fixed time points studied, we can-
not exclude the possibility that the true relationship of
C-peptide over time is polyphasic. In this regard, it is
worthwhile to recall that the baseline MMTT in TrialNet
studies is not performed until at least 21 days after di-
agnosis and that the median time from diagnosis for the
initial studies was 55 days; thus, we have no information
about the rate of fall from the time of diagnosis to the start
of our study. The rate of fall in C-peptide from ;2 months
until 14 months from diagnosis (e.g., 0–12 months from
study start) is distinct from the rate of fall from 14 to 26
months after diagnosis (e.g., 12–24 months after study
start). This data suggests that there may be metabolic or
immunological factors that differ soon after diagnosis
rather than later. This hypothesis would need to be ex-
plored further. With the caveat that MMTT- and oral glu-
cose tolerance test (OGTT)-stimulated C-peptide are not
equivalent (16), it is of interest to note that Diabetes
Prevention Trial–Type 1 (DPT-1) data show little change in
OGTT-stimulated C-peptide during the 30 months before
diagnosis, while a marked fall in peak C-peptide occurred
during the peridiagnosis period (17,18). Further insights
are likely to come from measuring C-peptide responses
under standardized conditions in individuals as they
progress from pre- to postdiagnosis. It is also important to
note that for these studies, virtually all patients had T1D
diagnosed in the community versus the diagnosis of usu-
ally asymptomatic T1D from surveillance OGTTs every
FIG. 2. Biphasic decline of mean AUC C-peptide over time.
TABLE 2
Multivariable analysis of baseline characteristics associated with fasting, peak, and AUC C-peptide over time
Covariate
AUC C-peptide Max C-peptide Fasting C-peptide
Relationship with
covariate across time
P
value
Relationship with
covariate across time
P
value
Relationship with
covariate across time
P
value
Age (continuous), years 0.00038 0.0024 0.00036 0.0504 0.00028 0.0047
Ethnicity (not Hispanic or
Latino is reference) 20.00113 0.6931
Race (white is reference) 20.00251 0.5079 20.00484 0.3631
BMI z score 20.00247 0.0152 20.00318 0.0247 20.00029 0.7195
ICA512 positivity 0.00447 0.0469 0.0656 0.1856 0.00220 0.2075
Diabetic ketoacidosis
(absent is reference) 0.00430 0.1156 0.00602 0.1176 0.00293 0.1684
HbA1c 20.00079 0.3165 20.00055 0.6209 0.00014 0.8189
Insulin (per kg) 0.01034 0.0438 0.01656 0.0202 0.00511 0.2017
Autoimmune disease history 0.00282 0.4386 0.0588 0.2536 20.00062 0.8272
Platelet count 20.00002 0.1934
Basophils 0.00516 0.0123 0.00841 0.0047 0.00323 0.0478
Antibody positive (0, 1, 2, or 3) NA 0.9910
GAD65 positivity 20.00140 0.7713
Platelet count 20.00002 0.3392 20.00002 0.1778
Polymorphonuclear leukocytes 20.00002 0.8821
NA, not applicable.
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6 months in DPT-1 and TrialNet Natural History and Pre-
vention studies (19–21). How the fall in C-peptide would
compare after these two very different methods of di-
agnosis is unknown but of major interest.
It is important to consider these data in the context of
results of clinical trials that have preserved b-cell function.
In these studies, the differences between the slopes (i.e.,
rate of fall) of C-peptide between placebo and treatment
groups were most pronounced early, with the slopes
appearing similar after this initial period (8,9,22,23). The
data presented in our analysis raise two hypotheses: 1) the
intervention may only affect the metabolic or immunologic
factors soon after diagnosis or 2) the rate of fall further
from diagnosis may be too flat to detect an effect of
intervention.
Our data also emphasize the variation in the rate of fall of
C-peptide over time and demonstrate that more than one-third
of subjects were “nonprogressors” experiencing an increase,
no change, or fall within the median CV of the MMTT at
least once in the 2 years of study. Approximately 1 in 6
subjects meet this definition at 1 year and .1 in 10 subjects
at 2 years after randomization. As a consequence, one must
be cautious about interpretation of small trials or in drawing
clinical conclusions from a single phase 2 study.
Similar to previous studies, we found that age, insulin
use at baseline, and BMI z score at baseline are significantly
FIG. 3. Model-based estimates of average slopes of AUC C-peptide over time according to age quartiles.
TABLE 3
Maintenance of C-peptide
Definition of maintenance of C-peptide*
n (%) of those who maintained C-peptide
Anytime through 2 years At 1 year At 2 years
“Percent” definition: Nonnegative change from baseline or
if negative, ,7.5% below baseline 95 (50) 28 (16) 17 (12)
“CV” definition: Nonnegative change from baseline or if
negative, less than median CV below baseline 73 (38) 33 (17) 21 (11)
“Inter-test” definition: Nonnegative change from baseline or
if negative, ,1 inter-test SD below baseline 119 (63) 43 (23) 29 (15)
*See RESEARCH DESIGN AND METHODS for details.
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associated with AUC and peak C-peptide over time in
multivariable analysis (24–26). It is notable that variables
such as class II HLA type as defined with three categories,
Tanner stage, and antibodies (number, positive or not, and
titer) that have been reported in previous studies to in-
fluence rate of b-cell function decline (27–30) were not
significantly associated with AUC or peak C-peptide over
time in our multivariable model. Further work to define the
role of genotype in disease progression is ongoing, in-
cluding more detailed analysis of HLA class I and II.
We were particularly interested in age both as a consid-
eration for future study design and to explore the question
about whether there are differences in disease progression
across the ages studied. The rate of decline of C-peptide
was similar in individuals aged 7 to 21 and greater than in
subjects older than 21 years. However, the youngest sub-
jects (aged 7 to 12) started with lower C-peptide than older
subjects aged 12 to 46 years. This observation is consistent
with clinical impressions that younger individuals fre-
quently have low levels of C-peptide but does not support
the idea that disease progression is different in younger
versus older children or that pubertal status influences the
disease process. A major caveat to this conclusion, how-
ever, is that the youngest subjects in this study were age 7.
Thus, our data do not permit any conclusions about
younger children. The different baseline C-peptide level in
the youngest group is consistent with the use of an age-
dependent percentile determination of intravenous glu-
cose tolerance test data that was used for assessing risk in
DPT-1 (31). Unfortunately, little information is available on
normal stimulated C-peptide values in young children,
a gap that limits our ability to interpret the data in indi-
viduals with disease. Our data clearly suggest differences
in disease progression between children and adults,
pointing to areas ripe for further investigation and also
emphasizing that a larger sample size may be required to
demonstrate a clinical effect of a drug if only adults are
studied. These older patients were diagnosed as T1D by
their providers. How their decline in b-cell function would
compare with so-called late autoimmune diabetes in adult
patients is unknown but also very important for potential
intervention trials.
The novel observation of the association of basophils
with change in C-peptide over time was unexpected. In-
deed, we initially evaluated white blood cell differentials to
examine how lymphopenia might relate to clinical course.
While historically conceptualized as related to mast cells
whose release of interleukin (IL)-4 and IL-13 may affect
allergy and protection from parasites, as recently reviewed
(32), basophils have multiple roles in the immune re-
sponse, including antibody production, serving as antigen
presenting cells, and amplifying the memory response
among others. Since higher basophil levels were associ-
ated with a less rapid fall in C-peptide over time, it is
tempting to speculate that this association is based on
a compensatory response to autoimmunity—attempting to
deviate cells via IL-4 cytokine release. However, this as-
sociation may also have occurred by chance and requires
replication in another dataset.
TrialNet studies were conducted at a limited number of
clinical centers, with close monitoring of glycemic control,
using a standardized approach to MMTT (with regard to
meals, insulin dosing, baseline glucose value, and time of
day), and centralized laboratories with quality assurance
programs. As such, combined data from these studies
provide a contemporaneous description of the natural
history of C-peptide under clinical trial conditions during
the first 2 years after randomization in a context by which
effects of intervention can be considered and future
studies designed. Since hyperglycemia itself has been as-
sociated with poor b-cell function (14), the rate of fall seen
in these studies in which individuals had a mean HbA1c of
6.5% on entry and 7.6% at 2 years may not reflect the natural
history of disease under usual clinical care. In addition,
many of the observations reported must be considered hy-
pothesis generating and require confirmation in additional
datasets. To this end, TrialNet will soon use data from two
additional studies: one using GAD65-alum (33) and the
other involving canakinumb to test the associations ob-
served in the trials used for the current analyses. These
studies are being conducted under identical circumstances
with the notable exception that subjects as young as age
3 are included in the GAD65 study, thus providing compar-
ative data in this important age-group.
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